Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (7326)	1/23/2004 1:11:43 PM
From: rkrw	Read Replies (1) \| Respond to of 10280

<<(I note that in the latest pipeline discussion SEPR talks about a steroid targeted at asthma, but that's along way off yet).>> Thanks. Strategically imo it would make a lot more sense to quickly proceed with flovent/arformoterol. Once arformoterol is approved that could quickly add another pivotal program. Assuming arformoterol will be appoved :-) Maybe it's not as exciting as depression or acute anxiety or a novel asthma steroid, but they'd likely get a much better risk adj return on their investment. To me this is what sepr was all about.